SequelSEC

Raphael Pharmaceutical Inc. RAPH

Medicinal Chemicals & Botanical Products · CIK 0001415397 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$1.24M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Raphael Pharmaceutical Inc. (RAPH) reported net income of -$1.28M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Raphael Pharmaceutical Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.

Income

Raphael Pharmaceutical Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.24M-$1.51M-$1.33M-$3.32M-$1.63M-$706.00K
Net income-$1.28M-$1.52M-$1.34M-$3.36M-$1.62M-$718.00K
Research & development$631.00K$776.00K$569.00K$1.18M$776.00K$461.00K
Weighted-average diluted sharesshares 19.55Mshares 18.67Mshares 16.72Mshares 14.34Mshares 11.17MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.07$0.08$0.08$0.23$0.15Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$614.00K$733.00K$763.00K$2.14M$853.00K$245.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Raphael Pharmaceutical Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalentsUnavailable$19.00K$230.00K$288.00K$153.00K$95.00K
Total assets$53.00K$27.00K$239.00K$333.00K$422.00K$323.00K
Current assets$51.00K$25.00K$237.00K$331.00K$422.00K$323.00K
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$1.49M$769.00K$132.00K$227.00K$294.00K$366.00K
Total equity incl. NCI-$1.43M-$742.00K$107.00K$106.00K$128.00K-$43.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$2.00K$2.00KUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$163.00K$125.00K$69.00KUnavailableUnavailableUnavailable

Cash flow

Raphael Pharmaceutical Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$210.00K-$532.00K-$1.20M-$759.00K-$1.42M-$779.00K
Capital expendituresUnavailableUnavailableUnavailable$2.00KUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable-$2.00KUnavailableUnavailable
Financing cash flow$236.00K$321.00K$1.14M$896.00K$1.48M$824.00K
Net change in cashUnavailableUnavailable-$58.00K$135.00K$58.00K$45.00K
Stock-based compensation$245.00K$350.00K$200.00K$2.29MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Raphael Pharmaceutical Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailable-$761.00KUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.03x0.03x1.80x1.46x1.44x0.88x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RAPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAWH ADIA AIBT BTMD CBDY CFOO CGC CHUC CRON CYAN DFTX FTLF

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.